VRTXVertex Pharmaceuticals
We are a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases, with a focus on specialty markets. 10-K, Item 1
- Employees
- 6,400
- Headquarters
- Boston, MA
- CEO
- Reshma Kewalramani
- Next results
- around Feb 11, 2027
From 2021 to 2025, CEO pay as reported rose 39% while net income rose 74%. $100 in the shares at the start of the table was worth $192 at the end (peer group: $125). CEO pay over the 5 years: $94.3M.
| Fiscal year to | CEO | CEO pay (reported) | CEO pay (actually paid) | Other executives, average | $100 became | Peer group | Net income | Net product revenue |
|---|---|---|---|---|---|---|---|---|
| Dec 31, 2025 | Reshma Kewalramani | $21.1M | $38.2M | $7.7M | $192 | $125 | $4.0B | $12.0B |
| Dec 31, 2024 | Reshma Kewalramani | $21.5M | $43.6M | $8.1M | $170 | $93 | -$500.0M | $11.0B |
| Dec 31, 2023 | Reshma Kewalramani | $20.6M | $44.2M | $7.4M | $172 | $94 | $3.6B | $9.9B |
| Dec 31, 2022 | Reshma Kewalramani | $15.9M | $29.5M | $9.0M | $122 | $90 | $3.3B | $8.9B |
| Dec 31, 2021 | Reshma Kewalramani | $15.2M | $18.3M | $7.2M | $93 | $100 | $2.3B | $7.6B |
Pay versus performance table of the proxy statement (DEF 14A) filed Apr 2, 2026, as tagged by the company in XBRL. Open the proxy ↗
Work on VRTX in a spreadsheet:
Excel workbook (a sheet per section, ten years by column, charts, links to the filings) ·
CSV.
For a Google Sheet that stays up to date, paste =IMPORTDATA("https://tickdelta.com/company/VRTX/export.csv") into a cell.